Breaking News Instant updates and real-time market news.

C

Citi

$48.99

0.39 (0.80%)

, INTC

Intel

$37.75

0.46 (1.23%)

07:35
10/19/16
10/19
07:35
10/19/16
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Tuesday in Citi (C), Intel (INTC), Chesapeake (CHK), Alcoa (AA), Teva (TEVA), CBS (CBS), Juniper (JNPR), Michael Kors (KORS), Hilton (HLT), and Shire (SHPG).

C

Citi

$48.99

0.39 (0.80%)

INTC

Intel

$37.75

0.46 (1.23%)

CHK

Chesapeake

$6.52

0.17 (2.68%)

AA

Alcoa

$26.51

0.16 (0.61%)

TEVA

Teva

$43.26

1.47 (3.52%)

CBS

CBS

$55.10

-0.29 (-0.52%)

JNPR

Juniper

$22.85

0.42 (1.87%)

KORS

Michael Kors

$47.52

0.97 (2.08%)

HLT

Hilton

$23.03

0.28 (1.23%)

SHPG

Shire

$190.70

4.91 (2.64%)

  • 20

    Oct

  • 20

    Oct

  • 23

    Oct

  • 25

    Oct

  • 26

    Oct

  • 26

    Oct

  • 26

    Oct

  • 03

    Nov

  • 06

    Nov

  • 09

    Nov

  • 09

    Nov

  • 11

    Nov

  • 14

    Nov

  • 15

    Nov

  • 15

    Nov

  • 16

    Nov

  • 08

    Dec

C Citi
$48.99

0.39 (0.80%)

10/10/16
OPCO
10/10/16
NO CHANGE
OPCO
Oppenheimer technical analyst upgrades Financials, downgrades Consumer Staples
Oppenheimer technical analyst Ari Wald upgraded the Financials sector to Market Weight and downgraded Consumer Staples to Underweight in next step in the firm's "cyclical rotation road map." Wald identified Ameriprise (AMP), Bank of America (BAC), Citi (C), Goldman Sachs (GS), Lincoln National (LNC) and SunTrust (STI) as six stocks breaking higher that he sees as likely to benefit from internal market rotation.
09/16/16
09/16/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. 21st Century Fox (FOX, FOXA) downgraded to Market Perform from Outperform at Bernstein with analyst Jason Park citing a reduction in his estimates for the company's Star India business. 2. Wells Fargo (WFC) downgraded to Underweight from Neutral at Atlantic Equities. 3. Citi (C) downgraded to Neutral from Buy at Goldman with analyst Richard Ramsden saying Citi's expected earnings inflection has failed to materialize and ROEs are at 7.7%, well below management's 10% target. 4. McCormick (MKC) downgraded to Market Perform from Outperform at Bernstein with analyst Alexia Howard citing valuation. 5. Novavax (NVAX) downgraded to Neutral from Overweight at Piper Jaffray, to Neutral from Overweight at JPMorgan, to Neutral from Buy at Ladenburg, to Neutral from Outperform at Wedbush, and to Neutral from Buy at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/16/16
GSCO
09/16/16
DOWNGRADE
GSCO
Neutral
Citi downgraded to Neutral from Buy at Goldman
Goldman analyst Richard Ramsden downgraded Citi to Neutral and lowered his price target on the shares to $50 from $52. The analyst said Citi's expected earnings inflection has failed to materialize and ROEs are at 7.7%, well below management's 10% target. Ramsden's analysis suggests growth in higher return businesses, such as credit cards and wealth management, and expense discipline will not be enough to increase ROE all the way to its 10% target. Citi remains a capital returns story, constrained by the utilization of deferred tax assets, the analyst wrote in his report.
10/11/16
COMP
10/11/16
INITIATION
Target $39
COMP
Sell
Citi initiated with a Sell at Compass Point
Compass Point analyst Charles Peabody initiated Citi with a Sell and a $39 price target saying earnings continue to look week combined with soft international and capital markets.
INTC Intel
$37.75

0.46 (1.23%)

10/19/16
JEFF
10/19/16
NO CHANGE
Target $46
JEFF
Buy
Intel Q4 outlook 'disappointing, but beatable,' says Jefferies
Jefferies analyst Mark Lipacis says Intel issued a "disappointing, but beatable" outlook for Q4. The guidance, which calls for below seasonal growth and gross margin decline of 180 basis points, appears conservative, Lipacis tells investors in a post-earnings research note. He lowered his price target for Intel shares to $46 from $49 but keeps a Buy rating on the name. The analyst likes the "gross margin setup" into 2017.
10/19/16
SUSQ
10/19/16
NO CHANGE
Target $42
SUSQ
Positive
Intel weakness a buying opportunity, says Susquehanna
Susquehanna analyst Christopher Rolland said weakness in Intel following Q3 results would be a great entry point for long-term investors. The analyst believes the decline in PC units will moderate and average selling prices will increase, which could mitigate the revenue decline. He also expects modest server acceleration and a new layer of revenue in non-CPU products. Rolland maintained his Positive rating and $42 price target on Intel shares.
10/19/16
STFL
10/19/16
NO CHANGE
STFL
Mellanox has positive read through from Intel results, says Stifel
Stifel analyst Kevin Cassidy says that the 32% growth of Intel's (INTC) revenue from Cloud Service providers last quarter bodes well for Mellanox (MLNX). The analyst estimates that Mellanox has roughly 32% revenue exposure to this market segment. He keeps an $85 price target and Buy rating on the shares.
10/19/16
STFL
10/19/16
NO CHANGE
STFL
Intel reported 'solid' results, says Stifel
Stifel analyst Kevin Cassidy says that Intel's results constituted "a solid beat" to its Q3 estimates, driven by PC inventory replenishment. The analyst says that the 32% jump in the company's revenue from Cloud Service providers was "most significant." He blames the company's revenue guidance miss primarily on the replenishment of the PC supply chain that took place last quarter. Cassidy expects investors to overlook this issue, and he keeps a $39 price target and Buy rating on the shares.
CHK Chesapeake
$6.52

0.17 (2.68%)

10/13/16
UBSW
10/13/16
NO CHANGE
Target $4
UBSW
Sell
Chesapeake liquidity better but debt still too high, says UBS
UBS analyst William Featherston previewed the Chesapeake analyst day and said he expects management to shift from its defensive strategy over the last two years to a more offensive one by targeting annual volume growth to resume in 2018. The analyst said the company's liquidity position has improved, but the debt level still remains too high. Featherston maintained his Sell rating and $4.50 price target on Chesapeake shares.
09/09/16
09/09/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Chesapeake (CHK) upgraded to Buy from Hold at Wunderlich with analyst Jason Wangler saying the company's assets are performing and its balance sheet is improving. 2. GameStop (GME) upgraded to Buy from Neutral at Hilliard Lyons. 3. Finisar (FNSR) upgraded to Buy from Neutral at MKM Partners with analyst Michael Genovese saying he is "extremely upbeat on the Optical components/module industry," and Chinese demand for 10G and 100G Optical modules appears it can stay strong for multiple years. 4. Randgold (GOLD) upgraded to Buy from Neutral at UBS with the firm citing the recent pullback in the shares and the potential for a dividend raise in 2017. 5. Teekay LNG (TGP) upgraded to Outperform from Market Perform at Wells Fargo analyst Michael Webber saying the discount to net asset value and the company's progress around financing its order book make the valuation "particularly compelling." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/09/16
WDLK
09/09/16
UPGRADE
Target $10
WDLK
Buy
Chesapeake upgraded to Buy from Hold at Wunderlich
Wunderlich analyst Jason Wangler upgraded Chesapeake Energy to Buy saying the company's assets are performing and its balance sheet is improving. The analyst raised his price target for the shares to $10 from $6.
09/13/16
FBRC
09/13/16
INITIATION
Target $5
FBRC
Underperform
Chesapeake initiated with an Underperform at FBR Capital
FBR Capital analyst Joseph Allman started Chesapeake Energy with an Underperform rating and $5 price target. The company's "debt and transportation commitments hole still appears too deep to dig out of," Allman tells investors in a research note. He views Chesapeake's equity as "significantly overvalued" and thinks the company's financial condition "will continue to be stressed."
AA Alcoa
$26.51

0.16 (0.61%)

10/12/16
10/12/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Norfolk Southern (NSC) downgraded to Underperform from Market Perform at Avondale with Donald Broughton saying he continues to believe volumes will continue to decline, yields will continue to disappoint, cost savings will be increasingly harder to achieve, return on invested capital will continue to deteriorate, and the combination of those factors should result in fiscal 2017 earnings below fiscal 2016, pressuring valuation. 2. Fortinet (FTNT) downgraded to Equal Weight from Overweight at Stephens with analyst Jonathan Ruykhaver saying he believes that in addition to slower overall growth in the network security market, heightened competition is impacting sales growth. 3. Alcoa (AA) downgraded to Neutral from Buy at BofA/Merrill with analyst Timna Tanners saying she believes Alcoa's aerospace-focused downstream segment will continue to struggle with execution issues and delays over the next several quarters. 4. Emerson (EMR) downgraded to Sell from Neutral at UBS with analyst Shannon O'Callaghan saying analysts need to lower estimates to reflect Emerson's portfolio transformation, pension headwinds and end market pressures. 5. Nanometrics (NANO) downgraded to Sector Weight from Overweight at Pacific Crest with analyst Weston Twigg saying 3D NAND equipment demand is likely to peak in 2017. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/11/16
BOFA
10/11/16
DOWNGRADE
BOFA
Neutral
Alcoa downgraded to Neutral from Buy at BofA/Merrill
09/09/16
09/09/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. American Express (AXP) initiated with an Underweight at Atlantic Equities. 2. Alcoa (AA) initiated with a Neutral at Seaport Global. 3. Blue Buffalo Pet Products (BUFF) initiated with an Outperform at Oppenheimer. 4. Harley-Davidson (HOG) initiated with an Outperform at Bernstein. 5. Verifone (PAY) initiated with a Buy at BTIG. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/12/16
10/12/16
DOWNGRADE
Target $30

Neutral
Alcoa downgraded to Neutral on aerospace issues at BofA/Merrill
As previously reported, BofA/Merrill downgraded Alcoa to Neutral from Buy and lowered its price target to $30 from $33. Analyst Timna Tanners believes Alcoa's aerospace-focused downstream segment will continue to struggle with execution issues and delays over the next several quarters. The analyst cut our estimates to reflect a weaker aerospace view and sees risk to Alcoa's guidance and continued margin pressures.
TEVA Teva
$43.26

1.47 (3.52%)

10/12/16
LEER
10/12/16
NO CHANGE
Target $70
LEER
Outperform
Neurocrine recent selloff a buying opportunity, says Leerink
Leerink analyst Paul Matteis views the 18% pullback in shares of Neurocrine Biosciences (NBIX) over the past few weeks as a buying opportunity. The analyst finds the catalyst for the selloff "difficult to pinpoint," but notes he's been receiving questions from investors on the size of the market opportunity for vesicular monoamine transporters in Tardive Dyskinesia. A doctor survey suggests a target market of 300,000 TD patients for Neurocrine's and Teva's VMAT2 inhibitors, which is enough to offer a "significant revenue opportunity" for both drugs, Matteis tells investors in a research note. Further, the analyst believes the upcoming Phase II data in Tourette's Syndrome, which he sees as having a high probability of success, offers a "nice catalyst for investors" into Q1 of next year. Matteis reiterates an Outperform rating on Neurocrine with a $70 price target.
10/11/16
LEHM
10/11/16
UPGRADE
Target $19
LEHM
Overweight
Momenta upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Douglas Tsao upgraded Momenta Pharmaceuticals to Overweight after attending the consolidated Copaxone 40mg trial. The analyst sees low risk of Momenta being blocked from the 40mg opportunity past 2018 and views the stock's risk/reward as "compelling" at current levels. Tsao believes there is a "good likelihood" that Sandoz, Momenta's partner, launches Copaxone 40mg at-risk as soon as February 2017 upon FDA approval when the 30-month stay expires. The analyst raised his price target for Momenta shares to $19 from $13.
10/07/16
LEER
10/07/16
NO CHANGE
Target $57
LEER
Outperform
Teva price target lowered to $57 from $61 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Teva to $57 from $61 and trimmed his estimates to reflect near-term headwinds and a more conservative Copaxone outlook. The analyst continues to view a generic Copaxone launch in late the second half of 2017 as a risk. Nonetheless, Gerberry reiterates an Outperform rating on the stock as he views shares as attractively valued despite near-term EPS concerns and believes investor attention will eventually pivot to Teva's attractive late stage pipeline.
10/06/16
WELS
10/06/16
NO CHANGE
WELS
Wells calls Teva partnership with Celltrion 'good news'
Wells Fargo analyst David Maris views Teva Pharmaceutical's partnership to commercialize two of Celltrion's monoclonal antibody biosimilar candidates as "good news." Teva is now a "little more firmly in the biosimilar game," Maris tells investors in a research note. He likes that the initial cash outflow is small and the partner. Maris has an Outperform rating on Teva.
CBS CBS
$55.10

-0.29 (-0.52%)

10/13/16
WELS
10/13/16
UPGRADE
WELS
Market Perform
Viacom upgraded to Market Perform from Underperform at Wells Fargo
Wells Fargo analyst Marci Ryvicker upgraded Viacom (VIAB) to Market Perform saying she believes shares are close to a floor. A merger with CBS (CBS) does not appear imminent, but if/when it does happen, CBS is unlikely to pay less than $32-$33 per Viacom share in a take-under, Ryvicker tells investors in a research note. The analyst has a $33-$35 price target range for Viacom shares. Ryvicker says that she still "REALLY" likes CBS and is cautious on CBS and Disney (DIS) into the Q3 earnings season.
10/14/16
RBCM
10/14/16
NO CHANGE
RBCM
CBS outlook positive says RBC Capital
RBC Capital analyst Steven Cahall expects CBS (CBS) to report "squeaky clean" Q3 results that includes a 1c EPS beat. The analyst is upbeat on a potential acquisition of Viacom (VIAB) by CBS, saying that the recent decline in Viacom's stock would improve accretion to CBS shareholders.
10/17/16
WEDB
10/17/16
UPGRADE
Target $46
WEDB
Outperform
Viacom upgraded to Outperform from Neutral at Wedbush
Wedbush analyst James Dix upgraded Viacom (VIAB) to Outperform citing increasing likelihood of a merger with CBS (CBS). The analyst assigns a 75% probability on a merger, which he assumes would be an all-stock transaction. He raised his price target for Viacom shares to $46 from $40.
10/17/16
WEDB
10/17/16
NO CHANGE
WEDB
CBS price target raised to $73 from $65 at Wedbush
Wedbush analyst James Dix says that CBS (CBS) is on track to merge with Viacom (VIAB), and he thinks that such a deal would be accretive to CBS' 2020 EPS. The analyst sees a 75% chance of a merger taking place, and he thinks that CBS' stock will advance even without a deal. He keeps a Buy rating on the shares.
JNPR Juniper
$22.85

0.42 (1.87%)

07/06/16
DBAB
07/06/16
DOWNGRADE
Target $22
DBAB
Hold
Juniper downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Vijay Bhagavath downgraded Juniper Networks to Hold saying his firm's Service Provider Channel research indicated the potential for margin pressure and share loss in the company's Routing business in FY17 and FY18. The analyst cut his price target for Juniper shares to $22 from $30.
10/14/16
MSCO
10/14/16
NO CHANGE
MSCO
Morgan Stanley positive on Arista, Cisco, cautious on F5 Networks, Juniper
Morgan Stanley analyst James Faucette favors Arista Networks (ANET), is positive on Cisco (CSCO) and cautious on F5 Networks (FFIV) and Juniper (JNPR) heading into Q3 results. The analyst expects another beat and raise for Arista and said increasing demand is straining availability but the company is prioritizing inventory to meet demand at hyperscales and the largest data center customers. Faucette expects Cisco to report in line results and said signs of stabilization in campus switch activity gives him confidence the strategy focus towards software and services will drive shares higher. He expects F5 to report an in line report with a modest improvement from new appliances ramp but is hearing crosscurrents on the longevity of the new product cycle. Finally, Faucette said Juniper's business continues to be below plan and is hearing instances of share loss in enterprise routers.
07/20/16
PIPR
07/20/16
NO CHANGE
PIPR
Piper survey shows networking infrastructure demand slowed meaningfully
Piper Jaffray analyst Troy Jensen says his firm's Q2 Networking survey, which consisted of 36 resellers/distributors located in the U.S. and Europe, indicated that demand for networking infrastructure saw a meaningful slowdown in the June quarter. The survey indicated demand was weak across most vendors, with "some of the worst results in recent memory" from Cisco (CSCO), Juniper (JNPR) and F5 Networks (FFIV), Jensen tells investors in a research note. The analyst recommends caution on the space heading into the Q2 earnings season.
07/01/16
OTRG
07/01/16
NO CHANGE
OTRG
Juniper's Q2 enterprise business stabilized, says OTR Global
OTR Global said Juniper's enterprise business stabilized during Q2, following the SAP implementation in January, and sales plan and win rate trends slightly quarter-over-quarter despite concerns about backlog.
KORS Michael Kors
$47.52

0.97 (2.08%)

10/17/16
10/17/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Wells Fargo (WFC) upgraded to Market Perform from Underperform at BMO Capital with analyst James Fotheringham. 2. AMD (AMD) upgraded to Perform from Underperform at Oppenheimer with analyst Rick Schafer citing lower balance sheet risk and improved near-term sales trends ahead of the company's third quarter results. 3. Groupon (GRPN) upgraded to Outperform from Neutral at Wedbush with analyst Aaron Turner saying he expects the company's "large valuation discrepancy" relative to peers to close following its third quarter earnings report. 4. Michael Kors KORS) upgraded to Mixed from Negative at OTR Global. 5. PNC Financial (PNC) upgraded to Buy from Hold at Argus with analyst Stephen Biggar saying PNC is well positioned to benefit from rising rates and it is making progress on a range of strategic initiatives, including expansion in the Southeast and in the Chicago area, where increased brand awareness has led to good growth in both retail and commercial banking. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/30/16
09/30/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Amazon.com (AMZN) initiated with a Buy at Guggenheim. 2. Wal-Mart (WMT) initiated with an Overweight at KeyBanc and a Buy at Guggenheim. 3. Harley-Davidson (HOG) initiated with a Hold at Jefferies. 4. Coach (COH) was initiated with a Buy at Guggenheim while the firm initiated Michael Kors (KORS) with a Neutral. 5. First Solar (FSLR) initiated with a Buy at Williams Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/04/16
WELS
10/04/16
NO CHANGE
WELS
Outperform
Coach still has upside as share retaken from Michael Kors, says Wells Fargo
Wells Fargo analyst Ike Boruchow believes that after Coach (COH) posted its first positive North American comp last quarter in over three years that it appears many investors have recently "moved on," viewing the turnaround story as played out. However, he thinks here is a long way to go should the brand continue to execute and finds it interesting that while investors were keenly aware of how much market share Michael Kors (KORS) was stealing over the past seven years, now it "doesn't seem like anyone is paying attention" as Coach finally takes back share at Kors' expense. Boruchow reiterate an Outperform rating and $46-$48 price target range on Coach share.
10/17/16
OTRG
10/17/16
UPGRADE
OTRG
Mixed
Michael Kors upgraded to Mixed from Negative at OTR Global
HLT Hilton
$23.03

0.28 (1.23%)

09/08/16
BERN
09/08/16
INITIATION
Target $26
BERN
Market Perform
Hilton initiated with a Market Perform at Bernstein
Bernstein analyst David Beckel initiated Hilton with a Market Perform and $26 price target.
07/06/16
WOLF
07/06/16
INITIATION
Target $28
WOLF
Outperform
Hilton initiated with an Outperform at Wolfe Research
Target $28.
05/19/16
05/19/16
DOWNGRADE
Target $23

Neutral
Hilton downgraded to Neutral on weak RevPAR trends at BofA/Merrill
As previously reported, BofA/Merrill downgraded Hilton to Neutral from Buy and lowered its price target to $23 from $26. Analyst Shaun Kelly said recent RevPAR trends put guidance at risk and near-term upside from a break-up of its businesses into three pieces is more limited given lower comp multiples.
05/19/16
05/19/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. L Brands (LB) downgraded to Neutral from Outperform at Baird and downgraded to Neutral from Buy at MKM Partners. Baird's analyst said near-term visibility has been greatly reduced amid the sales slowdowns on multiple fronts, while MKM Partners' Roxanne Meyer said decelerating comps and the change in leadership in lingerie signal that execution issues may continue. 2. Piper Jaffray analyst Stephanie Wissink downgraded Regis (RGS) Corporation to Underweight and lowered her price target for the shares to $8 from $13. The Department of Labor's overtime rule change, that will raise the minimum threshold for overtime eligibility from $23,660 to $47,500, could cost Regis $81M on a full year basis, Wissink tells investors in a research note. She lowered her estimates for the company "meaningfully." 3. BofA Merrill Lynch downgraded RLJ Lodging Trust (RLJ) two notches, to Underperform from Buy, and lowered its price target to $18 from $23. Analyst Shaun Kelley is concerned about RLJ's overexposure to Houston, New York City, Denver, and Chicago markets and thinks the loss of veteran CEO Tom Baltimore will take time to replace. The firm also downgraded Hyatt (H), Hersha Hospitality (HT) and Hilton (HLT), all to Neutral from Buy, this morning. 4. Goldman Sachs analyst Ryan Nash double downgraded BankUnited (BKU) to Sell from Buy and lowered his price target for the shares to $34 from $40. The analyst is concerned that consensus estimates for 2016 and 2017 are too high. 5. RBC Capital downgraded Lockheed Martin (LMT) to Sector Perform from Outperform, noting that the stock's valuation has reached a ten year high. RBC Capital also downgraded Northrop Grumman (NOC) to Sector Perform from Outperform, also citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SHPG Shire
$190.70

4.91 (2.64%)

08/03/16
LEER
08/03/16
NO CHANGE
Target $231
LEER
Outperform
Shire price target raised to $231 from $213 at Leerink
Leerink analyst Jason Gerberry raised his price target for Shire to $231 from $213 on valuation after the company reported "solid" Q2 results. The analyst reiterates an Outperform rating on the shares.
08/31/16
JEFF
08/31/16
NO CHANGE
Target $262
JEFF
Buy
Shire making right moves in dry eye market, says Jefferies
After hosting meetings with management, Jefferies analyst David Steinberg believes Shire (SHPG) is making "all the right moves" to make its dry eye drug Xiidra a potential $2B peak product in the U.S. Shire's Xiidra is competing with Allergan's (AGN) $1.4B dry eye drug Restasis, Steinberg tells investors in a research note. The analyst does not think Shire will have any problem exceeding the drug's consensus sales forecast of $200M for next year. He keeps a Buy rating on the shares with a $262 price target.
09/26/16
HSBC
09/26/16
DOWNGRADE
HSBC
Hold
Shire downgraded to Hold from Buy at HSBC
HSBC analyst Steve McGarry downgraded SHire to Hold saying valuation is no longer compelling.
09/26/16
LEER
09/26/16
NO CHANGE
LEER
Shire Xiidra launch to 'significantly' expand dry eye category, says Leerink
Leerink analyst Jason Gerberry remains optimistic that Shire's (SHPG) Xiidra launch will "significantly" expand the category for dry eye disease brands, while not meaningfully eroding Allergan's (AGN) Restasis market leading position. While it's still early in the launch of Xiidra and payer access remains a critical variable, the analyst does not anticipate access being a major barrier. Gerberry reiterates an Outperform rating on both Shire and Allergan's shares.

TODAY'S FREE FLY STORIES

ANET

Arista Networks

$94.41

-1.35 (-1.41%)

, CSCO

Cisco

$30.06

0.11 (0.37%)

18:32
12/09/16
12/09
18:32
12/09/16
18:32
Hot Stocks
Arista Networks favored in ITC initial determination on four of six patents »

Arista Networks (ANET)…

ANET

Arista Networks

$94.41

-1.35 (-1.41%)

CSCO

Cisco

$30.06

0.11 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

TKTDY

Takata Corporation

$10.70

0.05 (0.47%)

18:22
12/09/16
12/09
18:22
12/09/16
18:22
Periodicals
U.S. DOT looks to accelerate pace of Takata air bag replacements, Reuters says »

The U.S. Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DV

DeVry

$31.90

0.9 (2.90%)

18:17
12/09/16
12/09
18:17
12/09/16
18:17
Hot Stocks
Breaking Hot Stocks news story on DeVry »

International Value…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CSOD

Cornerstone OnDemand

$39.10

-0.11 (-0.28%)

18:10
12/09/16
12/09
18:10
12/09/16
18:10
Periodicals
Cornerstone OnDemand considers sale amid activist pressure, Bloomberg reports »

Cornerstone OnDemand has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$0.12

-0.0014 (-1.17%)

18:03
12/09/16
12/09
18:03
12/09/16
18:03
Hot Stocks
NYSE MKT says CEL-SCI noncompliant with certain listing requirements »

CEL-SCI reported on a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$89.00

0.68 (0.77%)

18:01
12/09/16
12/09
18:01
12/09/16
18:01
Periodicals
Exxon CEO Tillerson emerges as top candidate for secretary of state, WSJ says »

Exxon Mobil CEO Rex…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FUL

H.B. Fuller

$50.36

0.05 (0.10%)

17:58
12/09/16
12/09
17:58
12/09/16
17:58
Hot Stocks
H.B. Fuller announces restructuring, to eliminate, relocate 220 positions »

H.B. Fuller has announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$287.77

-1.77 (-0.61%)

17:53
12/09/16
12/09
17:53
12/09/16
17:53
Periodicals
Biogen looks like a bargain, Barron's reports »

Biogen trades at just…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$40.40

0.63 (1.58%)

17:42
12/09/16
12/09
17:42
12/09/16
17:42
Periodicals
Sanofi to lay off 20% of U.S. diabetes, cardiovascular staff, Bloomberg says »

The layoffs include parts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

CSOD

Cornerstone OnDemand

$39.10

-0.11 (-0.28%)

17:38
12/09/16
12/09
17:38
12/09/16
17:38
Periodicals
Cornerstone OnDemand considers sale amid activist pressure, Bloomberg reports »

Investor Praesidium said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TACO

Del Taco

$14.75

-0.39 (-2.58%)

17:34
12/09/16
12/09
17:34
12/09/16
17:34
Hot Stocks
Breaking Hot Stocks news story on Del Taco »

PW Acquisitions cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 09

    Jan

  • 09

    Dec

UNVR

Univar

$26.36

0.54 (2.09%)

, BXLT

Baxalta

17:30
12/09/16
12/09
17:30
12/09/16
17:30
Hot Stocks
Univar names Eric Foster chief information officer »

Univar (UNVR) named Eric…

UNVR

Univar

$26.36

0.54 (2.09%)

BXLT

Baxalta

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PARN

Parnell

$1.42

-0.0031 (-0.22%)

17:30
12/09/16
12/09
17:30
12/09/16
17:30
Hot Stocks
Breaking Hot Stocks news story on Parnell 

Parnell trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$20.81

0.2 (0.97%)

, NVRO

Nevro

$76.38

-1.88 (-2.40%)

17:24
12/09/16
12/09
17:24
12/09/16
17:24
Hot Stocks
Boston Scientific files patent infringement suit against Nevro »

Nevro (NVRO) announced…

BSX

Boston Scientific

$20.81

0.2 (0.97%)

NVRO

Nevro

$76.38

-1.88 (-2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

RTN

Raytheon

$146.30

0.14 (0.10%)

17:21
12/09/16
12/09
17:21
12/09/16
17:21
Hot Stocks
Raytheon awarded $101.9M government contract »

Raytheon Co., Goleta,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CX

CEMEX

$8.77

-0.16 (-1.79%)

17:18
12/09/16
12/09
17:18
12/09/16
17:18
Hot Stocks
CEMEX receives subpoena from SEC regarding Foreign Corrupt Practices Act »

On December 9, 2016,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PDEX

PRO-DEX

$4.48

0.034 (0.76%)

17:06
12/09/16
12/09
17:06
12/09/16
17:06
Syndicate
Breaking Syndicate news story on PRO-DEX »

PRO-DEX files $25M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFBX

Peoples Financial

$14.50

-0.5 (-3.33%)

17:02
12/09/16
12/09
17:02
12/09/16
17:02
Hot Stocks
Breaking Hot Stocks news story on Peoples Financial »

Jeffrey L. Gendell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QUIK

QuickLogic

$0.94

-0.0163 (-1.71%)

17:00
12/09/16
12/09
17:00
12/09/16
17:00
Syndicate
Breaking Syndicate news story on QuickLogic »

QuickLogic files $40M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STRZA

Starz

17:00
12/09/16
12/09
17:00
12/09/16
17:00
Hot Stocks
Breaking Hot Stocks news story on Starz »

Elliott Associates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BEL

Belmond

16:55
12/09/16
12/09
16:55
12/09/16
16:55
Syndicate
Breaking Syndicate news story on Belmond »

Belmond files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PARN

Parnell

$1.42

-0.0031 (-0.22%)

16:55
12/09/16
12/09
16:55
12/09/16
16:55
Hot Stocks
Breaking Hot Stocks news story on Parnell »

Parnell trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$43.73

0.15 (0.34%)

, SHAK

Shake Shack

$38.08

0.82 (2.20%)

16:50
12/09/16
12/09
16:50
12/09/16
16:50
Hot Stocks
Breaking Hot Stocks news story on Morgan Stanley, Shake Shack »

Morgan Stanley reports…

MS

Morgan Stanley

$43.73

0.15 (0.34%)

SHAK

Shake Shack

$38.08

0.82 (2.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

MS

Morgan Stanley

$43.73

0.15 (0.34%)

, LXFT

Luxoft

$54.40

-1.8 (-3.20%)

16:44
12/09/16
12/09
16:44
12/09/16
16:44
Hot Stocks
Breaking Hot Stocks news story on Morgan Stanley, Luxoft »

Morgan Stanley reports…

MS

Morgan Stanley

$43.73

0.15 (0.34%)

LXFT

Luxoft

$54.40

-1.8 (-3.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FUL

H.B. Fuller

$50.36

0.05 (0.10%)

16:44
12/09/16
12/09
16:44
12/09/16
16:44
Hot Stocks
H.B. Fuller announces restructuring plan »

On December 7, H.B.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.